Trial design {8}
TB, pulmonary TB
This will be an open-label, phase IIb, randomized, controlled, dose-finding, multi-centre study in participants with newly diagnosed, smear-positive, uncomplicated drug-sensitive pulmonary TB. Adult participants (≥ 18 years of age) will be randomized by centralized allocation at a ratio of 1:1:1:1:1 to one of five treatment arms containing BDQ, DLM and MXF, combined with different doses of DZD.After the completion of 16 weeks of experimental treatment, participants in the experimental arms, who did not achieve two successive negative liquid media cultures with the first at or before week 08, with no following positive results reported by the week 16 visit, will be referred to their local health care facility to complete their course of anti-TB treatment according to the national TB program. All other participants will be followed up until week 52 to rule out relapse or re-infection.